1 terminated. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Terminated 1 |
Follow mRNA-1647: new trials by email Literature Review of mRNA-1647 trials Research Report on mRNA-1647
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age mRNA-1647, Placebo - Cytomegalovirus Infection | Phase 3 | Terminated | ModernaTX, Inc. | 7454 | 2021-10-26 | 2025-12-15 |
Cytomegalovirus Infections (1) · DNA Virus Infections (1) · Virus Diseases (1)
ModernaTX, Inc. (1)
Australia (1) · Belgium (1) · Canada (1) · Estonia (1) · Finland (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · Spain (1) · United Kingdom (1) · United States (1)
PMID 36102707, PMID 37899366, PMID 38190492
2023 (1)